Perimenopause is frequently discussed as a physical event. For a significant proportion of women, the most disruptive symptoms are psychological, and they are consistently under-recognised in primary care.
Oestrogen is a neuroactive steroid. Beyond its reproductive role, it modulates serotonergic, dopaminergic and noradrenergic systems, HPA axis reactivity, hippocampal neuroplasticity and sleep architecture. During the perimenopausal transition, oestrogen does not decline in an orderly fashion — it fluctuates, often considerably, before stabilising at lower post-menopausal levels. It is this fluctuation, rather than the eventual low stable state, that is most strongly associated with psychological disruption.
The clinical presentation does not always resemble textbook depression or anxiety. It frequently includes irritability and disproportionate anger rather than low mood, anxiety without clear cognitive content, and cognitive changes — reduced verbal fluency, word-finding difficulty, slowed processing — that are subjectively alarming but often do not appear on standard neuropsychological testing. For the majority of women these cognitive changes are transient rather than progressive.
Research has identified perimenopause as a window of vulnerability for mood disorders. Longitudinal data indicate that women are approximately twice as likely to develop clinically significant depressive symptoms during perimenopause than during the premenopausal period, independent of prior psychiatric history or psychosocial stressors. This suggests a neurobiological contribution that is distinct from the undeniable psychosocial load of this life stage.
A clinically relevant implication follows. Where psychological symptoms are primarily driven by hormonal fluctuation, response to psychological intervention alone may be limited, and a hormonal evaluation is warranted as part of a comprehensive assessment. This is a matter for individual clinical judgement, not a blanket recommendation — but it is a consideration that is frequently omitted.
For late-diagnosed autistic and ADHD women, the transition can produce a marked escalation of baseline difficulties, as declining oestrogen affects dopaminergic function and reduces the capacity for sustained masking and compensation. This population is currently underserved by existing menopause guidance.
The central clinical point is one of framing. Psychological symptoms emerging in the mid-forties to mid-fifties warrant consideration of the hormonal transition alongside psychosocial and psychiatric formulation — not in isolation from it.
Dr Melanie du Preez